Business Wire

CA-ALTIUM-LLC

18.8.2022 07:02:11 CEST | Business Wire | Press release

Share
Altium, IPC Education Foundation, and Arduino Announce Student Electronics Design Competition

Altium LLC, the leading printed circuit board (PCB) design software company, is partnering with the IPC Education Foundation (IPCEF) and Arduino to launch the second annual student electronics design challenge. This competition aims to engage, educate, and enhance PCB design capabilities while developing STEM solutions to environmental challenges. The electronics design challenge is an excellent opportunity for students to showcase their talents and gain real-world experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005660/en/

The Innovation for Environmental Change 2022 International Student Design Competition (#PCBeTheChange) engages student teams to help address common environmental concerns using Altium’s educational tools with Arduino hardware.

Over 17 countries submitted entries to last year's competition , which addressed various local environmental issues, including city traffic, shoreline erosion, bushfire detection, honey bee endangerment, and more.

Teams will use Altium Upverter Modular PCB design software and the Arduino Portenta H7 to create prototype designs that will improve the environment in each team's respective local area. The teams will be challenged to tackle one or more environmental concerns, such as air pollution, water quality, and solar energy capture.

As Yu Hu, head of Arduino Education, elaborates, “At Arduino, we believe that it is very crucial to empower the scientists and engineers of the future to address the common challenges of our time by using technology for the benefit of many. Last year’s entries showed an amazing combination of ingenuity, curiosity, and technical skills in their designs, and we’re excited to see what new and innovative STEM solutions the teams will submit this year.”

Participating teams will enter the design challenge while harnessing Altium Upverter Education and the Upverter Modular tool. Altium features multiple educational initiatives designed to support high school STEM teachers and students, along with programs to support college students and industry professionals.

“It was fascinating to see 87 teams from around the world participate, leveraging the printed circuit board design knowledge they had learned from Altium’s Upverter Education, to address important environmental issues. We are excited to see more unique designs from this year’s contestants and are honored to again have the opportunity to provide the curriculum and tools students need for the contest,” adds Rea Callender, vice president of education at Altium.

Winning teams will be eligible to win cash prizes for each category: high school and college: $1500 (1st prize), $750 (2nd prize) and $500 (3rd prize), free access to IPC APEX EXPO in San Diego, California from January 24-26, 2023. Designs will be displayed at the IPC Design Booth; awards will be presented at the IPC APEX EXPO STEM Outreach Event.

Charlene Gunter, senior director of IPCEF shares, “ We believe that opportunities and experiences like this will allow students to gain awareness and access to the electronics manufacturing industry and in turn help them reach their career goals. This collaboration with Altium, Upverter Education, and Arduino showcases our mutual goals of engaging and educating students in PCB design, and we look forward to seeing the creativity and solutions the teams will create this year.”

Open registration for the design challenge is available now via Upverter Education and runs through Monday, October 3. Teams must submit their designs online by Friday, November 18. Competition winners will be announced on Wednesday, December 14, followed by virtual presentations for the first place and runner-up entrants.

For more information, please contact upverter.education@altium.com .

About Altium

Altium, LLC (ASX:ALU ) is a global software company headquartered in San Diego, California, accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

About Upverter Education

Upverter Education , launched by Altium in September 2020, is addressing an important societal need by empowering STEM educators teaching engineering, electronics design, and robotics with free essential tools and classroom resources. The program has been honored with multiple awards, including the EdTech Breakthrough Award, for Best Engineering Learning Solution and the Gold STEVIE® American Business Award, further validating Altium’s innovative approach to supporting STEM education.

About IPC Education Foundation (IPCEF)

The IPC Education Foundation creates awareness of the careers the electronics manufacturing industry has to offer students in high school and college by providing them with opportunities to access people, courses, and knowledge through key programs: 1) The IPC Student Chapter program provides scholarships, industry-standard education, industry connections, and access to hands-on competitions, especially with the support of industry experts and professionals; 2) IPC Video Subscription Libraries provide access to industry-relevant content to students in high school and college, and 3) a variety of engagement initiatives like in-person/virtual events, webinars, and classroom activities.

About Arduino

Arduino is the leading open-source hardware and software company in the world. Born to provide an easy-to-use platform for anyone making interactive projects, Arduino has reached a growing community and adapted to new needs and challenges, branching out into products for IoT, wearables, 3D printing, and embedded environments. As of today, the Arduino community included approximately 30 million active users.

Social Media:

https://www.facebook.com/AltiumOfficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye